Literature DB >> 11038624

Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation.

B M Keck1, L E Bennett, J Rosendale, O P Daily, R J Novick, J D Hosenpud.   

Abstract

1. The number of heart transplant operations performed in the US has increased by 51 procedures between 1997 (2,294) and 1998 (2,345). The number of lung transplants decreased by 67 in 1998 (862). 2. The most frequently reported indication for heart transplantation in the US is coronary artery disease (44.6%). For other thoracic transplants, the most frequently reported indications include other/unknown (43.9%) for double lung, emphysema/COPD (53.5%) for single lung and other/unknown (53.2%) for heart-lung. The most frequently reported diagnoses for thoracic transplantation outside the US include cardiomyopathy (50.5%) for heart, cystic fibrosis (32.0%) for double lung, idiopathic pulmonary fibrosis (32.7%) for single lung and congenital heart disease (24.7%) for heart-lung. 3. US heart transplant recipients were predominately male (77%), between 50-64 years old (51.4%) and White (81.7%). In contrast, US lung transplant recipients are predominantly female (51.3%), between 50-64 years of age (44.7%) and White (89.7%). No meaningful variance from the US recipient demographic profile was noted for the non-US recipients during the same time period. 4. Pediatric recipients (< 18 years of age) received 10.9% of the reported heart transplants and 6.5% of reported lung transplants. 5. One-year survival for thoracic transplants performed in the US was 83.2% for heart, 70.6% for lung and 62.5%. Five-year survival for US thoracic transplants was 70% for heart and 49.1% for lung. 6. Long-term patient survival rates were: 22.3% at 18 years for heart, 20% at 9 years for lung and 25% at 12 years for heart-lung recipients. 7. The most important risk factor for mortality of US heart recipients at one month, one and 5 years after transplantation was receipt of a previous heart transplant. Significant short-term risk factors included donor age, recipient age and ischemic time. Substantial long-term risk factors include older donor age, donor race and recipient race. 8. The factors having the most significant impact on lung mortality at all time points were related to either the patient's medical condition (e.g., in the ICU prior to transplant, requiring mechanical ventilation) or diagnosis. 9. Mechanical ventilation and previous transplant had the largest impact on heart-lung mortality. 10. For heart and lung recipients, the major cause of hospitalization during the first posttransplant year was infection.

Entities:  

Mesh:

Year:  1999        PMID: 11038624

Source DB:  PubMed          Journal:  Clin Transpl        ISSN: 0890-9016


  9 in total

1.  Engineered fetal cardiac graft preserves its cardiomyocyte proliferation within postinfarcted myocardium and sustains cardiac function.

Authors:  Kazuro L Fujimoto; Kelly C Clause; Li J Liu; Joseph P Tinney; Shivam Verma; William R Wagner; Bradley B Keller; Kimimasa Tobita
Journal:  Tissue Eng Part A       Date:  2011-01-16       Impact factor: 3.845

2.  Extracellular matrix-derived peptides and myocardial repair.

Authors:  Shirley S Mihardja; Jiashing Yu; Randall J Lee
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

3.  The universal NF-kappaB inhibitor a20 protects from transplant vasculopathy by differentially affecting apoptosis in endothelial and smooth muscle cells.

Authors:  S Daniel; V I Patel; G V Shrikhande; S T Scali; H E Ramsey; E Csizmadia; N Benhaga; M D Fisher; M B Arvelo; C Ferran
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

4.  Levels of circulating CXCR4-positive cells are decreased and negatively correlated with risk factors in cardiac transplant recipients.

Authors:  Colin Gerard Egan; Francesca Caporali; Pier Leopoldo Capecchi; Pietro Enea Lazzerini; Franco Laghi Pasini; Vincenzo Sorrentino
Journal:  Heart Vessels       Date:  2010-10-30       Impact factor: 2.037

5.  Surgical ventricular restoration: the RESTORE Group experience.

Authors:  Constantine L Athanasuleas; Gerald D Buckberg; Alfred W H Stanley; William Siler; Vincent Dor; Marisa DiDonato; Lorenzo Menicanti; Sergio Almeida de Oliveira; Friedhelm Beyersdorf; Irving L Kron; Hisayoshi Suma; Nicholas T Kouchoukos; Wistar Moore; Patrick M McCarthy; Mehmet C Oz; Francis Fontan; Meredith L Scott; Kevin A Accola
Journal:  Heart Fail Rev       Date:  2004-10       Impact factor: 4.214

Review 6.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 8.  TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection.

Authors:  Adam J Booth; D Keith Bishop
Journal:  Immunotherapy       Date:  2010-07       Impact factor: 4.196

Review 9.  Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions.

Authors:  José F Bernardo; Jerry McCauley
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.